5-AMINOSALICYLIC ACID ASSOCIATED CHRONIC TUBULOINTERSTITIAL NEPHRITIS IN A PATIENT WITH CROHN'S DISEASE

Year 2000, Volume: 13 Issue: 4, 226 - 229, 03.12.2016

Mehmet Koç İshak Çetin Özener Azra Bihorac İşın Kılıçaslan Emel Akoğlu

Abstract

5-Aminosalicyiic acid (5-ASA) is the most commonly used drug for the treatment of inflammatory bowel disease (IBD). 5- aminosalicylic acid induced nephrotoxicity has recently been reported. We report a case of female with Crohn's disease treated with mesalazine for 60 months and sulphasalazine for additional 12 months. The patient presented with loin pain, sterile pyuria and raised serum creatinine. Percutaneous renal biopsy revealed chronic interstitial nephritis and yellow-brown pigment deposition in proximal tubular cells. Steroid treatment was commenced for 4 months and there has been no improvement in renal function. Due to widespread use of mesalazine, and its insidious onset of nephrotoxicity, renal function screening and urinalysis should be routinely performed to detect the toxicity of mesalazine and related drugs.
Key Words: Chronic interstitial nephritis, 5- ASA, Sulphasalizine, mesalazine.

References

• Witte T, Olbricht CJ, Koch KM. Interstitial nephritis associated with 5-aniinosalicylic acid, hiephron 1994;67:481-482.
• De Droe ME- Stoiear JC, non wen EJ, et al. 5- aminosolicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease; is there a link? nephrol Dial Transplant 1997;12:1839-1841.
• liamling J, Kaedler A, flelmhen U, et al. 5- aminosalicylic acid - associated renal tubular acidosis with decreased renal function in chron's disease. Digestion 1997;58:304-307.
• Chronic interstitial nephritis and 5-ASA
• Korzets Z, Bernheim J. Minimal-change nephropathy induced by 5-aminosalicylic acid. Nephrol Dial Transplant 1996; 11:1817- 1818.
• Rhodes JM, Masson EA. Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss. Gut 1992:33:563- 564.
• World MJ, Stevens PE, Ashton MA, et al. Mesalazine associated interstitial nephritis. Nephrol Dial Transplant 1996; 11:614-621.
• Riley S/4, Lloyd DR, Mani V. Test of renal function in patients with quiescent colitis. Gut 1992;33:1348-1352.
• Casadevall G, Moreno JJ, Franch MA, et al. N- acetyl-D glucosaminidase (NAG) and alanine aminopeptidase (AAP) excretion after acute administration of acetaminophen, salsalate and aspirin in rats. Res Commun Chem Pathol Pharmacol 1983;81:77-89.
• Schreiber S, flamling J, Zehnter F, et al. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut 1997;40:761-766.
• Duggin GG. Mechanisms in the development of analgesic nephropathy. Kidney Int 1980;18:553-561.
• Nadasdy T, Racusen LC. Renal injury caused by therapeutic and diagnostic agents and abuse of analgesics and narcotics. Jeanette JC, Olson JL, Schwartz MM, Silva FG, eds. FieptinstalTs Pathology of the Kidney, 5^’ ed. Philadelphia: Lippincott-Raven Publishers, 1998:81 1,861.
• Robson M, Levi J, Dolberg L, Rosental JB. Acute interstitial nephritis following sulfadiazine therapy. Isr J Med Sei 1970;6:561-566.
• Chester AC, Diamond Lit, Schreiner GE. Hypersensitivity to salicylazopyridine. Renal and hepatic toxic reactions. Arch Intern Med 1978,138:1 138-1 139.
• Barbour VM, Williams PF. Nephrotic syndrome associated with sulphasalazine. BMJ 1990:301:818.
• Dwarakanath AD, Michael J, Allan RN. Sulphasalazine induced renal failure. Gut 1992;33:1006-1007.
• Appel GB, Neu HC. The nephrotoxicity of antimicrobial agents (third of three parts). No Engl J Med 1977;296:784-787.